170 related articles for article (PubMed ID: 31654481)
1. Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration.
Mitsch C; Pemp B; Pollreisz A; Gleiss A; Karst S; Scholda C; Sacu S; Schmidt-Erfurth U
Acta Ophthalmol; 2020 May; 98(3):e301-e308. PubMed ID: 31654481
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab treatment improves diabetic macular oedema without influencing retinal oximetry parameters.
Takasago Y; Fujita T; Nakano Y; Osaka R; Miyake M; Muraoka Y; Tsujikawa A
Acta Ophthalmol; 2019 Dec; 97(8):e1048-e1053. PubMed ID: 31127694
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
4. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal aflibercept treatment on retinal vessel parameters in diabetic macular oedema:
Sabaner MC; Doğan M; Duman R
Cutan Ocul Toxicol; 2019 Sep; 38(3):267-273. PubMed ID: 31010334
[No Abstract] [Full Text] [Related]
6. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V
J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843
[TBL] [Abstract][Full Text] [Related]
7. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
[TBL] [Abstract][Full Text] [Related]
9. Long-term dynamic changes and influencing factors of corneal morphology after multiple intravitreal injections of anti-VEGF drugs.
Qi Y; Li C; Ye S; Zhang Z; Li S; Zhang L
Medicine (Baltimore); 2024 Apr; 103(17):e37937. PubMed ID: 38669379
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
Blindbæk SL; Peto T; Grauslund J
Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
[TBL] [Abstract][Full Text] [Related]
11. Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial.
Blindbaek SL; Peto T; Grauslund J
Acta Ophthalmol; 2020 Jun; 98(4):353-359. PubMed ID: 31654501
[TBL] [Abstract][Full Text] [Related]
12. Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
Kim SW; Woo JE; Yoon YS; Lee S; Woo JM; Min JK
Curr Pharm Des; 2019; 25(2):184-189. PubMed ID: 30892159
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
14. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
15. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
16. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
[TBL] [Abstract][Full Text] [Related]
18. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]